Psychotrophic mechanisms of action of antiepileptic drugs in mood disorder

Antiepileptic Drugs to Treat Psychiatric Disorders

Volumn , Issue , 2008, Pages 379-399

  Post, Robert M ^a  

^a Bipolar Collaborative Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 66649095409     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780849382666-24     Document Type: Chapter

References (85)

1. Marangell LB, George MS, Callahan AM, et al. Effects of intrathecal thyrotropinreleasing hormone (protirelin) in refractory depressed patients. Arch Gen Psychiatry 1997; 54:214-222.
2. Szuba MP, Amsterdam JD, Fernando AT III, et al. Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression. J Clin Psychopharmacol 2005; 25:325-330.
3. Maeng S, Zarate CA Jr., Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylsoxazole-4-propionic acid receptors. Biol Psychiatry 2008; 63(4):349-352.
4. Preskorn SD, Baker B, Omo K, et al. A placebo- controlled trial of the NR2B specific NMDA antagonist CP-101, 606 plus paroxetine for treatment resistant depression. 160th Annual Meeting of the American Psychiatric Association, San Diego, CA, 2007 (New Research Abstracts No.362).
5. Manji HK, Duman RS. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 2001; 35:5-49.
6. Zarate CA Jr., Singh JB, Carlson PJ, et al Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 2007; 9:561-570.
7. Post RM, Speer AM, Obrocea, GV, et al Acute and prophylactic effects of anticonvulsants in bipolar depression. Clin Neurosci Res 2002; 2:228-251.
8. Geddes JR, Burgess H, Hawton K, et al. Long-term lithium treatment therapy for bipolar disorder: systemic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161(2): 217-22.
9. Cipriani A, Smith K, Burgess S, et al. Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. Cochrane Database Syst Rev 2006; 168(4):CD003492.
10. Post RM, Berrettini W, Uhde TW, et al. Selective response to the anticonvulsant carbamazepine in manic-depressive illness: a case study. J Clin Psychopharmacol 1984; 4: 178-185.
11. Greil W, Kleindienst N. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int Clin Psychopharmacol 1999; 14(5):283-285.
12. Greil W, Kleindienst N. The comparative prophylactic efficacy of lithium and carbama-zepine in patients with bipolar I disorder. Int Clin Psychopharmacol 1999; 14(5):277-281.
13. Greil W, Kleindienst N, Erazo N, et al. Differential response to lithium and carbama-zepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998; 18:455-460.
14. Bowden CL. Predictors of response to divalproex and lithium. J Clin Psychiatry 1995; 56(suppl 3):25-30.
15. Calabrese JR, Fatemi SH, Woyshville MJ. Antidepressant effects of lamotrigine in rapid cycling bipolar disorder. Am J Psychiatry 1996; 153:236.
16. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20:607-614.
17. Obrocea GV, Dunn RM, Frye MA, et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 2002; 51: 253-260.
18. van der Loos ML, Kolling P, Knoppert-van der Klein EA et al. Lamotrigine as add-on to lithium in bipolar depression, 160th Annual Meeting American Psychiatric Association, San Diego, CA, New Research Abstract No.286, p.20.
19. Passmore MJ, Garnham J, Duffy A, et al. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord 2003; 5:110-114.
20. Alda M. The phenotypic spectra of bipolar disorder. Eur Neuropsychopharmacol 2004; 14(suppl 2): S94-S99.
21. Grof P. Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. J Clin Psychiatry 2003; 64(suppl 5):53-61.
22. Du J, Suzuki K, Wei Y, et al. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 2007; 32:793-802.
23. Mishory A, Yaroslavsky Y, Bersudsky Y, et al. Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry 2000; 157:463-465.
24. Post RM, Speer AM. A brief history of anticonvulsant use in affective disorders. In: Trimble MR, Schmitz B, eds. Seizures, Affective Disorders and Anticonvulsant Drugs. Surrey, UK: Clarius Press, 2002:53-81.
25. Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipolar disorder: a placebocontrolled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000; 2(3 pt 2):249-255.
26. Grunze H, Erfurth A, Marcuse A, et al. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999; 60:759-762.
27. Suppes T, Chisholm KA, Dhavale D, et al. Tiagabine in treatment-refractory bipolar disorder: a clinical case series. Bipolar Disord 2002; 4:283-289.
28. Post RM, Altshuler LL, Frye MA, et al. Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. J Clin Psychiatry 2005; 66:370-374.
29. Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002; 136:659-672.
30. Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia 2001; 4:13-18.
31. Klitgaard H, Matagne A, Gobert J, et al. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998; 353(2-3):191-206.
32. Post RM. Animal models of mood disorders: kindling as a model of affective illness progression. In: Schachter S, Holmes G, Kasteleijn-Nolst Trenite D, eds. Behavioral Aspects of Epilepsy: Principles and Practice. New York, NY: Demos Medical Publishing, 2008.
33. McElroy SL, Suppes T, Keck PE Jr.., et al. Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. J Clin Psychiatry 2005; 66(5):617-624.
34. McElroy SL, Kotwal R, Guerdjikova AI, et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry 2006; 67(12): 1897-1906.
35. Maitre M, Mandel P. [Properties allowing the attribution to gamma-hydroxybutyrate the quality of neurotransmitter in the central nervous system] C R Acad Sci III 1984; 298(12):341-345.
36. B receptors are up-regulated by chronic treatment with lithium or carbamazepine: GABA hypothesis of affective disorders. Eur J Pharmacol 1989; 166:95-99.
37. van Calker D, Belmaker RH. The high affinity inositol transport system-implications for the pathophysiology and treatment of bipolar disorder. Bipolar Disord 2000; 2(2):102-107.
38. Hough CJ, Irwin RP, Gao XM, et al. Carbamazepine inhibition of N-methyl-D-aspartate-evoked calcium influx in rat cerebellar granule cells. J Pharmacol Exp Ther 1996; 276(1):143-149.
39. Manji HK, Moore GJ, Rajkowska G, et al. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000; 5(6):578-593.
40. Chuang DM, Chen RW, Chalecka-Franaszek E, et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 2007; 4(2):129-136.
41. Einat H, Yuan P, Gould TD, et al. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 2003; 13; 23(19):7311-7316.
42. Chen PS, Wang CC, Bortner CD, et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 2007; 149(1):203-212.
43. Beutler AS, Li S, Nicol R, et al. Carbamazepine is an inhibitor of histone deacetylases. Life Sci 2005; 76(26):3107-3115.
44. Sherman WR, Leavitt AL, Honchar MP, et al. Evidence that lithium alters phosphoi-nositide metabolism: chronic administration elevates primarily D-myo-inositol-1-phosphate in cerebral cortex of the rat. J Neurochem 1981; 36:1947-1951.
45. Post RM, Weiss SRB, Clark M, et al. Lithium, carbamazepine and valproate in affective illness. In Manji HK, Bowden CL, Belmaker RH, eds. Bipolar Medications: Mechanisms of Action. Washington, DC: Am Psychiatric Press, Inc., 2000:219-248.
46. Post RM, Luckenbaugh DA. Unique design issues in clinical trials of patients with bipolar affective disorder. J Psychiatr Res 2003; 37(1):61-73 (review).
47. Wagner KD, Kowatch RA, Emslie GJ, et al. A double-blind, randomized, placebocontrolled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006; 163(7):1179-1186.
48. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59(12):1116-1127.
49. Post RM. Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res 2007; 41(12):979-990.
50. Sheline YI, Wang PW, Gado MH, et al. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A 1996; 93(9):3908-3913.
51. Moore GJ, Bebchuk JM, Wilds IB, et al. Lithium-induced increase in human brain grey matter. Lancet 2000; 356:1241-1242.
52. Bearden CE, Thompson PM, Dalwani M, et al. Reply: lithium and Increased Cortical Gray Matter-More Tissue or More Water? Biol Psychiatry 2008; 63(3):E19.
53. Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for one year with daily prospective ratings on the NIMH-Life Chart Method. J Clin Psychiatry 2003; 64:680-690.
54. Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev 2007; 31(6):858-873.
55. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992; 149: 999-1010.
56. Post RM, Leverich GS. The role of psychosocial stress in the onset and progression of bipolar disorder and its comorbidities: the need for earlier and alternative modes of therapeutic intervention. Dev Psychopathol 2006; 18:1181-1211.
57. Leverich GS, McElroy SL, Suppes T, et al. Early physical and sexual abuse associated with an adverse course of bipolar illness. Biol Psychiatry 2002; 51(4):288-297.
58. Leverich GS, Altshuler LL, Frye MA, et al. Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. J Clin Psychiatry 2003; 64(5):506-515.
59. Leverich GS, Post RM, Keck PE Jr., et al. The poor prognosis of childhood-onset bipolar disorder. J Pediatr 2007; 150: 485-490.
60. Perlis RH, Miyahara S, Marangell LB, et al. Long-Term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2004; 55(9):875-881.
61. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62(6):593-602.
62. Baldessarini RJ, Tondo L, Baethge CJ, et al. Effects of treatment latency on response to maintenance treatment in manic-depressive disorders. Bipolar Disord 2007; 9(4): 386-393.
63. Lange KJ, McInnis MG. Studies of anticipation in bipolar affective disorder. CNS Spectr 2002; 7(3):196-202.
64. Velisek L, Velishkova J, Ptachewich Y, et al. Age-dependent effects of gamma-aminobutyric acid agents on flurothyl seizures. Epilepsia 1995; 36(7): 636-643.
65. Pinel JP. Kindling-induced experimental epilepsy in rats: cortical stimulation. Exp Neurol 1981; 72(3):559-569.
66. Weiss SR, Clark M, Rosen JB, et al. Contingent tolerance to the anticonvulsant effects of carbamazepine: relationship to loss of endogenous adaptive mechanisms. Brain Res Rev 1995; 20:305-325.
67. Post R, Uhde T, Kramlinger K, et al. Carbamazepine treatment of mania: clinical and biochemical aspects. Clin Neuropharmacol 1986; 4:547-549.
68. Prudic J, Olfson M, Marcus SC, et al. Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry 2004; 55(3):301-312.
69. Sackeim HA, Prudic J, Olfson M. Response to Drs Abrams and Kellner: the cognitive effects of ECT in community settings. J ECT 2007; 23(2):65-67.
70. Rush AJ, Sackeim HA, Marangell LB, et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 2005; 58(5): 355-363.
71. Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58(5):347-354.
72. Nemeroff CB, Mayberg HS, Krahl SE, et al. VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology 2006; 31(7):1345-1355.
73. McElroy SL, Hudson JI, Capece JA, et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 2007; 61(9): 1039-1048.
74. Berlant JL. Topiramate in posttraumatic stress disorder: preliminary clinical observations. J Clin Psychiatry 2001; 62(suppl 17):60-63.
75. Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry 2002; 63(1):15-20.
76. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999; 19(4):341-348.
77. Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20:467-471.
78. Johnson BA. Uses of topiramate in the treatment of alcohol dependence. Expert Rev Neurother 2004; 4(5):751-758.
79. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JaMa 2007; 298(14):1641-1651.
80. Johnson BA. Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs 2005; 19(10):873-896.
81. McElroy SL, Shapira NA, Arnold LM, et al. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry 2004; 65(11):1463-1469.
82. McIntyre RS, Mancini DA, McCann S, et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 2002; 4(3):207-213.
83. Dahlof C, Loder E, Diamond M, et al. The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebocontrolled clinical trials. Health Qual Life Outcomes 2007; 5(1):56.
84. Post RM, Speer AM, Hough CJ, et al. Neurobiology of bipolar illness: implications for future study and therapeutics. Ann Clin Psychiatry 2003; 15:85-94.
85. Tucker P, Trautman RP, Wyatt DB, et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68(2):201-206.